Noninvasive molecular imaging of tuberculosis-associated inflammation with radioiodinated DPA-713

Journal of Infectious Diseases

Volumn 208, Issue 12, 2013, Pages 2067-2074

  Foss, Catherine A ^a,b   Harper, Jamie S ^a   Wang, Haofan ^b   Pomper, Martin G ^a,b   Jain, Sanjay K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Russell H Morgan Department of Radiology and Radiological Sciences   (United States)

Author keywords

Macrophage; Molecular imaging; PET; Pyrazolopyrimidine; Translocator protein; Tuberculosis

Indexed keywords

CARRIER PROTEIN; CD68 ANTIGEN; DPA 713; FLUORODEOXYGLUCOSE F 18; IODO DPA 713 I 125; PYRAZOLOPYRIMIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR; ACETAMIDE DERIVATIVE; BZRP PROTEIN, MOUSE; N,N-DIETHYL-2-(2-(4-METHOXYPHENYL)-5,7-DIMETHYL-PYRAZOLO(1,5-A)PYRIMIDIN-3-YL)-ACETAMIDE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; N,N DIETHYL 2 (2 (4 METHOXYPHENYL) 5,7 DIMETHYL PYRAZOLO(1,5 A)PYRIMIDIN 3 YL) ACETAMIDE; PYRAZOLOPYRIMIDINE; TRANSLOCATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CELLULAR DISTRIBUTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; EX VIVO STUDY; FEMALE; FLUORESCENCE ANALYSIS; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; INFLAMMATION; MACROPHAGE; MOLECULAR IMAGING; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NON INVASIVE PROCEDURE; NONHUMAN; PHAGOCYTE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECT SCANNER; TISSUE DISTRIBUTION; TUBERCULOSIS; WHOLE BODY IMAGING; ANIMAL; BAGG ALBINO MOUSE; C3H MOUSE; CHEMISTRY; GRANULOMA; LUNG; METABOLISM; PATHOLOGY; PNEUMONIA; PROCEDURES; METHODOLOGY; PET;

ACETAMIDES; ANIMALS; FEMALE; GRANULOMA; LUNG; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MOLECULAR IMAGING; PHAGOCYTES; PNEUMONIA; PYRAZOLES; PYRIMIDINES; RECEPTORS, GABA; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TUBERCULOSIS;

MACROPHAGE; MOLECULAR IMAGING; PET; PYRAZOLOPYRIMIDINE; TRANSLOCATOR PROTEIN; TUBERCULOSIS;

EID: 84897119487     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit331     Document Type: Article

References (42)

1. Higgins LJ, Pomper MG. The evolution of imaging in cancer: current state and future challenges. Semin Oncol 2011; 38:3-15.
2. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005-15.
3. Zelmer A, Carroll P, Andreu N, et al. A new in vivo model to test antituberculosis drugs using fluorescence imaging. J Antimicrob Chemother 2012; 67:1948-60.
4. Andreu N, Zelmer A, Wiles S. Noninvasive biophotonic imaging for studies of infectious disease. FEMS Microbiol Rev 2011; 35:360-94.
5. Kong Y, Yao H, Ren H, et al. Imaging tuberculosis with endogenous beta-lactamase reporter enzyme fluorescence in live mice. Proc Natl Acad Sci U S A 2010; 107:12239-44.
6. Ning X, Lee S, Wang Z, et al. Maltodextrin-based imaging probes detect bacteria in vivo with high sensitivity and specificity. Nat Mater 2011; 10:602-7.
7. Clay H, Volkman HE, Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 2008; 29:283-94.
8. Egen JG, Rothfuchs AG, Feng CG, Winter N, Sher A, Germain RN. Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. Immunity 2008; 28: 271-84.
9. Kei PL, Kok TY, Padhy AK, Ng DC, Goh AS. [18F] FDG PET/CT in patients with fever of unknown origin: A local experience. Nucl Med Commun 2010; 31:788-92.
10. Keidar Z, Gurman-Balbir A, Gaitini D, Israel O. Fever of unknown origin: The role of 18F-FDG PET/CT. J Nucl Med 2008; 49:1980-5.
11. Meller J, Sahlmann CO, Scheel AK. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med 2007; 48:35-45.
12. Davis SL, Nuermberger EL, Um PK, et al. Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother 2009; 53:4879-84.
13. Sathekge M, Maes A, Kgomo M, Stoltz A, Van de Wiele C. Use of 18F-FDG PET to predict response to first-line tuberculostatics in HIV associated tuberculosis. J Nucl Med 2011; 52:880-5.
14. Bell GI, Burant CF, Takeda I, Gould GW. Structure and function of mammalian facilitative sugar transporters. J Biol Chem 1993; 268:19161-4.
15. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B. FDG accumulation and tumor biology. Nucl Med Biol 1998;25:317-22.
16. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and in-flammation. Semin Nucl Med 2002; 32:47-59.
17. Rupprecht R, Papadopoulos V, Rammes G, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 2010; 9:971-88.
18. Zavala F, Haumont J, Lenfant M. Interaction of benzodiazepines with mouse macrophages. Eur J Pharmacol 1984; 106:561-6.
19. Endres CJ, Pomper MG, James M, et al. Initial evaluation of 11CDPA-713, a novel TSPO PET ligand, in humans. J Nucl Med 2009; 50:1276-82.
20. Fujimura Y, Zoghbi SS, Simeon FG, et al. Quantification of translocator protein (18 kDa) in the human brain with PET and a novel radioligand, (18)F-PBR06. J Nucl Med 2009; 50:1047-53.
21. Bird JL, Izquierdo-Garcia D, Davies JR, et al. Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis. Atherosclerosis 2010; 210: 388-91.
22. Zheng J, Boisgard R, Siquier-Pernet K, Decaudin D, Dolle F, Tavitian B. Differential expression of the 18 kDa translocator protein (TSPO) by neoplastic and inflammatory cells in mouse tumors of breast cancer. Mol Pharm 2011; 8:823-32.
23. Kam WW, Meikle SR, Dunstan CR, Banati RB. The 18 kDa translocator protein (peripheral benzodiazepine receptor) expression in the bone of normal, osteoprotegerin or low calcium diet treated mice. PLoS One 2012; 7:e30623.
24. Hatori A, Yui J, Yamasaki T, et al. PET imaging of lung inflammation with [(18)F]FEDAC, a radioligand for translocator protein (18 kDa). PLoS One 2012; 7:e45065.
25. Wang H, Pullambhatla M, Guilarte TR, Mease RC, Pomper MG. Synthesis of [(125)I]iodoDPA-713: A new probe for imaging inflammation. Biochem Biophys Res Commun 2009; 389:80-3.
26. Pan H, Yan BS, Rojas M, et al. Iprl gene mediates innate immunity to tuberculosis. Nature 2005; 434:767-72.
27. Harper J, Skerry C, Davis SL, et al. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis 2012; 205: 595-602.
28. Doorduin J, Klein HC, Dierckx RA, James M, Kassiou M, deVries EF. [11CJ-DPA-713 and [18F]-DPA-714 as new PET tracers for TSPO: A comparison with [ 11C]-(R)-PK 11195 in a rat model of herpes encepha-litis. Mol Imaging Biol 2009; 11:386-98.
29. Davis SL, Be NA, Lamichhane G, et al. Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals. PLoS One 2009; 4:e6297.
30. Savoie JC, Thomopoulos P, Savoie F. Studies on monoand diiodohistidine. I. The identification of iodohistidines from thyroidal iodoproteins and their peripheral metabolism in the normal man and rat. J Clin Invest 1973; 52:106-15.
31. Favreau F, Rossard L, Zhang K, et al. Expression and modulation of translocator protein and its partners by hypoxia reoxygenation or ischemia and reperfusion in porcine renal models. Am J Physiol Renal Physiol 2009; 297:F177-90.
32. Batarseh A, Papadopoulos V. Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states. Mol Cell Endocrinol 2010; 327:1-12.
33. Fenton MJ, Vermeulen MW. Immunopathology of tuberculosis: roles of macrophages and monocytes. Infect Immun 1996; 64:683-90.
34. WHO. Global tuberculosis control: WHO report. Geneva: Global Tuberculosis Programme, World Health Organization, 2012.
35. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55:301-5.
36. Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drugresistant tuberculosis or totally drug-resistant strains in iran. Chest 2009; 136:420-5.
37. Schluger NW. Tuberculosis clinical trials: past, present and future. Presented at Keystone Symposia. Tuberculosis: from lab research to field trials, Vancouver, Canada. March 20-25, 2007.
38. Ramprasad MP, Terpstra V, Kondratenko N, Quehenberger O, Steinberg D. Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipo-protein. Proc Nad Acad Sci U S A 1996; 93:14833-8.
39. Hardwick MJ, Chen MK, Baidoo K, Pomper MG, Guilarte TR. In vivo imaging of peripheral benzodiazepine receptors in mouse lungs: A biomarker of inflammation. Mol Imaging 2005; 4:432-8.
40. Boutin H, Chauveau F, Thominiaux C, et al. 11C-DPA-713: A novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation. J Nucl Med 2007; 48:573-81.
41. Endres CJ, Coughlin JM, Gage KL, Watkins CC, Kassiou M, Pomper MG. Radiation Dosimetry and Biodistribution of the TSPO Ligand 11C-DPA-713 in Humans. J Nucl Med 2012; 53:330-5.
42. Sexton M, Woodruff G, Cudaback E, et al. Binding of NIR-conPK and NIR-6 T to astrocytomas and microglial cells: evidence for a protein related to TSPO. PLoS One 2009; 4:e8271.